Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-08-14
2007-08-14
Landsman, Robert S. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S009100, C435S007100, C435S007200, C530S402000
Reexamination Certificate
active
09787356
ABSTRACT:
The present invention relates generally to a method of inducing, stimulating or otherwise facilitating bronchoprotection in humans and animals by modulating bronchial constriction and/or inflammation. The present invention is predicated in part on the identification of receptors in airway epithelium which mediate inhibition of bronchoconstriction and/or inflammation following their activation. More particularly, the present invention identifies that activation of protease activated receptors (PARs) results in relaxation of airway epithelium. Activation of airway epithelium PARs inhibits bronchoconstriction and/or inflammation and thereby mediates bronchoprotection of the airways. The present invention further provides a method for the prophylaxis and treatment of disease conditions in airways such as asthma and bronchitis and further provides methods for the diagnosis and screening of agents useful in the prophylaxis and treatment of airway disease conditions.
REFERENCES:
patent: 6323219 (2001-11-01), Costanzo
Cicala C, et al. British J. Pharmacol. 122:PROC SUPPL pp14P, Oct. 1997.
“Ligand Cross-Reactivity Within the Protease-Activated Receptor Family” Brian D. Blackhart, et al, The Journal of Biological Chemistry, 1996, vol. 271, No. 28, Issue of Jul. 12, pp. 16466-16471, 1996.
“Characterization of a Functional Thrombin Receptor”, Issues and Opportunities by Shaun R. Coughlin, et al, J. Clin. Invest., The American Society for Clinical Investigation, Inc., vol. 89, Feb. 1992, 351-355.
“Endothelium-Dependent Hyperpolarization: A Role in the Control of Vascular Tone”, by Christopher J. Garland, et al., TiPS—Jan. 1995, vol. 16, pp. 23-30.
“Protease Activated Receptor 3 is a Second Thrombin Receptor in Humans” by Hiroaki Ishihara, et al., Nature, vol. 386, Apr. 3, 1997, pp. 502-506.
“Interactions of Mast Cell Tryptase With Thrombin Receptors and PAR-2”, by Marina Molino, et al, The Journal of Biological Chemistry, vol. 272, No. 7, Issue of Feb. 14, pp. 4043-4049, 1997.
“In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse” by Steven R. Schwarze, et al., Science, vol. 285, Sep. 3, 1999; pp. 1659-1572.
“Molecular Cloning of a Functional Thrombin Receptor Reveals a Novel Proteolytic Mechanism of Receptor Activation” by Thien-Khai H. Vu, et al., Cell, vol. 64, 1057-1068, Mar. 22, 1991.
Akers, I.A. et al., “Human lung fibroblasts express PAR-2 which mediate the mitogenic effects of mast cell tryptase” Faseb J., vol. 12, No. 4, p. A434, (1998).
Joliot A. et al., “Cell biology” vol. 4, 2ndedition, pp. 111-119, Academic Press Inc. (1998).
Vives et al., “A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus” Journal of Biological Chemistry, American Society of Biological Chemists, Baltimore, MD, US, vol. 272, No. 25, pp. 16010-16017, (1997).
Cocks Thomas Matthew
Moffatt James David
Knobbe Martens Olson & Bear LLP
Landsman Robert S.
The University of Melbourne
LandOfFree
Method of treatment and agents useful for same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment and agents useful for same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment and agents useful for same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3899715